Drug Profile
Research programme: anthrax vaccine - Bavarian Nordic
Alternative Names: MVA-BN AnthraxLatest Information Update: 09 Oct 2015
Price :
$50
*
At a glance
- Originator Bavarian Nordic
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 09 Oct 2015 Discontinued - Preclinical for Anthrax (Prevention) in Germany (Parenteral)
- 17 Dec 2014 Bavarian Nordic has patent protection for MVA-BN® technology in USA and Europe